Centessa Pharmaceuticals (CNTA) Total Current Liabilities (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Total Current Liabilities data on file, last reported at $36.6 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $36.6 million, up 51.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $36.6 million (up 51.12% YoY), and the FY2025 annual result was $42.9 million, down 25.97% from the prior year.
• Total Current Liabilities retreated to $36.6 million in Q1 2026 per CNTA's latest filing, from $42.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $58.0 million in Q4 2024 and troughed at $24.2 million in Q1 2025.
• A 5-year average of $33.9 million and a median of $33.6 million in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities jumped 55.61% in 2022, then dropped 25.97% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $38.3 million in 2022, then advanced by 2.73% to $39.4 million in 2023, then jumped by 47.26% to $58.0 million in 2024, then fell by 25.97% to $42.9 million in 2025, then declined by 14.82% to $36.6 million in 2026.
• Business Quant data shows CNTA's Total Current Liabilities at $36.6 million in Q1 2026, $42.9 million in Q4 2025, and $29.1 million in Q3 2025.